Welcome to our dedicated page for ANGLE PLC S/ADR news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on ANGLE PLC S/ADR stock.
ANGLE PLC S/ADR (ANPCY) is a world-leading liquid biopsy company specializing in innovative circulating tumour cell (CTC) solutions for research, drug development, and clinical oncology. The company's proprietary Parsortix system efficiently harvests CTCs from blood samples, enabling downstream molecular analysis for comprehensive biomarker assessment. ANGLE's cutting-edge technologies, such as the Portrait+ CTC Staining Kit, enable the identification and analysis of diverse CTC phenotypes and clusters, providing valuable insights into cancer progression, metastasis, and treatment response. With a focus on diagnostic products and clinical services, ANGLE continues to drive advancements in precision medicine through its state-of-the-art liquid biopsy solutions.
Rhea-AI Summary
ANGLE plc has secured US and EU patents for its CellKeep slide, reducing over 70% of CTC cell loss during microscopy, enhancing assay sensitivity. The innovative device improves CTC attachment to slides, increasing cell preservation and reducing costs. The technology significantly boosts identification rates of CTCs and biomarkers, advancing precision medicine for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
ANGLE plc (ANPCY) presents Parsortix HER2 assay at AACR Annual Meeting 2024, showcasing a novel assay for HER2 assessment on circulating tumor cells. The assay, developed in collaboration with BioView, aims to evaluate HER2 gene amplification and protein expression in metastatic breast cancer patients. The presented data demonstrates successful identification of HER2 positive CTCs, potentially benefiting patients who may require HER2-targeted therapies. Liquid biopsy evaluation offers a minimally invasive technique for monitoring HER2 status over time, providing valuable data for treatment decisions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
ANGLE plc showcases Parsortix system and assays at a leading European Breast Cancer Conference. The company presents two posters highlighting the utility of its new Portrait+ CTC Staining Kit and Portrait HER2 assay. ANGLE's technology enables comprehensive analysis of circulating tumor cells, including mesenchymal CTCs and CTC clusters, crucial for cancer progression and metastasis. The company's IF assay for HER2 status in CTCs offers a minimally invasive alternative to tissue biopsies, allowing for dynamic monitoring and potential clinical decision-making in metastatic breast cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
ANGLE plc announces breakthrough data from a newly established workflow for real-time parallel Next Generation Sequencing (NGS) DNA analysis of both ctDNA and CTCs from a single tube of patient blood. The peer-reviewed paper in 'Current Issues in Molecular Biology' highlights the potential utility of Parsortix CTC harvest in precision oncology. The study showcases the benefits of utilizing the Parsortix system for downstream molecular analysis across various cancer types. The findings demonstrate the value of a dual analyte approach for both CTCs and ctDNA in informing prognosis, treatment selection, monitoring of treatment resistance, and disease relapse.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
ANGLE plc (TR-1): Notification of Major Holdings by Global Frontier Investments, LLC and Global Frontier Partners, LP
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
ANGLE plc (AIM:AGL OTCQX:ANPCY) has signed a contract with Eisai Inc. for a pilot study worth US $250,000 to provide CTC analysis with its Portrait HER2 assay to assess breast cancer patients' HER2 status in a Phase II study of the HER2 targeting antibody-drug conjugate (ADC) BB-1701, offering potential for multiple large-scale follow-up studies. The global HER2+ breast cancer ADC market is predicted to reach US $3.3 billion per annum by 2030, and ANGLE's Portrait HER2 assay enables accurate stratification of patient populations throughout the treatment pathway. The company's CEO, Andrew Newland, highlighted the potential of the study for major expansion of this line of business going forward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
ANGLE plc (AGL) announces Berenberg as Nominated Adviser and Sole Broker. The company, a leader in liquid biopsy and CTC diagnostic solutions, will benefit from Berenberg's expertise in this strategic partnership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) announces a breakthrough publication by researchers at the University of New Mexico, US, regarding the use of Parsortix system in pre-clinical model for gene expression profiling associated with melanoma brain metastasis. The study reveals the system's pivotal role in prescribing more targeted treatments based on patient needs, with a positive impact on therapeutic regime effectiveness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) launches Portrait+ CTC staining kit, combining Parsortix technology with an immunofluorescent assay for precise CTC identification, characterisation, and enumeration. The test is designed for accurate, repeatable results and can be used in breast, lung, prostate, and ovarian cancers. EMT transition step in cancer cells is also detected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.87%
Tags
Rhea-AI Summary
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) expects a 120% increase in revenue for 2023 to c. £2.2 million, with sales secured in 2023 expected to be c. £3.3 million. Revenue for 2024 is expected to triple compared to 2023. The cash runway has been extended into Q2 2025. The streamlining of the Services business is expected to result in cost savings of c. £3 million per annum in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of ANGLE PLC S/ADR (ANPCY)?
The current stock price of ANGLE PLC S/ADR (ANPCY) is $1.35 as of December 18, 2024.
What is the market cap of ANGLE PLC S/ADR (ANPCY)?
The market cap of ANGLE PLC S/ADR (ANPCY) is approximately 47.4M.
What is ANGLE PLC S/ADR known for?
ANGLE is a world-leading liquid biopsy company specializing in innovative circulating tumour cell (CTC) solutions for research, drug development, and clinical oncology.
What technologies does ANGLE use for CTC analysis?
ANGLE utilizes the Parsortix system for efficient harvesting of CTCs from blood samples, enabling downstream molecular analysis for comprehensive biomarker assessment.
How does ANGLE's Portrait+ CTC Staining Kit benefit cancer research?
The Portrait+ CTC Staining Kit enables the identification and analysis of diverse CTC phenotypes and clusters, providing valuable insights into cancer progression, metastasis, and treatment response.
What is the focus of ANGLE's commercial businesses?
ANGLE's commercial focus is on diagnostic products and clinical services, offering advanced liquid biopsy solutions and custom assay development for pharma.
ANGLE PLC S/ADR